Optimization of GPC3-specific Chimeric Antigen Receptor Structure and Its Effect on Killing Hepatocellular Carcinoma Cells

Overview

Journal Bioengineered

Date 2021 Jul 15

PMID 34261411

Citations 6

Authors

Jianfeng Zhao

Lijuan Lin

Yihua Luo

Qinghe Cai

Xiaojie Jiang

Changxi Liao

Huimin Wei

Affiliations

Soon will be listed here.

Abstract

To investigate the effect of optimized GPC3-specific chimeric antigen receptor (GPC3-CAR) structure on killing hepatocellular carcinoma (HCC) cells. We constructed three lentiviral expression vectors with different CAR structures by genetic engineering and molecular cloning techniques. These three CAR structures shared the same intracellular signaling region consisting of 4-1BB and CD3ζ, but had different hinge and transmembrane regions. Specifically, GPC3-O4-CAR contained an optimized CD8α hinge region and a 4-1BB transmembrane domain; GPC3-CD8-CAR contained an optimized CD8α hinge region and a CD8α transmembrane domain; and GPC3-ori-CAR contained an original CD8α hinge region and a 4-1BB transmembrane domain. With similar transfection efficiency, it was observed by fluorescence microscopy that GPC3-O4-CAR expression on the surface of 293 T cells was much higher than those of the other two. Cytotoxicity experiments showed that T or NK cells with GPC3-O4-CAR structure were more lethal and could secrete more IFN-γ than the other two. In conclusion, GPC3-O4-CAR can be efficiently and stably expressed on the cell surface. Moreover, both the killing effect of transduced T and NK cells on GPC3-positive HCC cells and release of IFN-γ are increased.

Citing Articles

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.

Zhu X, Xue J, Jiang H, Xue D Mol Cancer. 2024; 23(1):237.

PMID: 39443938 PMC: 11515662. DOI: 10.1186/s12943-024-02151-3.

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.

Wang Y, Jin S, Zhuang Q, Liu N, Chen R, Adam S MedComm (2020). 2023; 4(6):e422.

PMID: 38045827 PMC: 10691297. DOI: 10.1002/mco2.422.

A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma.

Huang X, Li F, Li T, Zhang J, Shi X, Huang X J Nanobiotechnology. 2023; 21(1):25.

PMID: 36681851 PMC: 9867854. DOI: 10.1186/s12951-023-01783-9.

Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma.

Shen J, Yang D, Ding Y Cancers (Basel). 2022; 14(20).

PMID: 36291802 PMC: 9599749. DOI: 10.3390/cancers14205018.

Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8 T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Zheng Y, Lu Z, Ding J, Jiang N, Wang J, Yang J Cancers (Basel). 2022; 14(18).

PMID: 36139670 PMC: 9497125. DOI: 10.3390/cancers14184512.

References

Zhu A, Gold P, El-Khoueiry A, Abrams T, Morikawa H, Ohishi N . First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013; 19(4):920-8. DOI: 10.1158/1078-0432.CCR-12-2616. View

Feins S, Kong W, Williams E, Milone M, Fraietta J . An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019; 94(S1):S3-S9. DOI: 10.1002/ajh.25418. View

Abou-Alfa G, Meyer T, Cheng A, El-Khoueiry A, Rimassa L, Ryoo B . Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1):54-63. PMC: 7523244. DOI: 10.1056/NEJMoa1717002. View

Cleary K, Chan H, James S, Glennie M, Cragg M . Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. J Immunol. 2017; 198(10):3999-4011. PMC: 5424080. DOI: 10.4049/jimmunol.1601473. View

Durinck K, Wallaert A, Van de Walle I, Van Loocke W, Volders P, Vanhauwaert S . The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia. Haematologica. 2014; 99(12):1808-16. PMC: 4258754. DOI: 10.3324/haematol.2014.115683. View

Hudecek M, Sommermeyer D, Kosasih P, Silva-Benedict A, Liu L, Rader C . The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2014; 3(2):125-35. PMC: 4692801. DOI: 10.1158/2326-6066.CIR-14-0127. View

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M . Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2017; 32(2):520-531. PMC: 6063081. DOI: 10.1038/leu.2017.226. View

Dees S, Ganesan R, Singh S, Grewal I . Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer. Mol Cancer Ther. 2020; 19(12):2409-2421. DOI: 10.1158/1535-7163.MCT-20-0385. View

Gao H, Li K, Tu H, Pan X, Jiang H, Shi B . Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014; 20(24):6418-28. DOI: 10.1158/1078-0432.CCR-14-1170. View

10.

Wang Y, Zhu Z, Teng D, Yao Z, Gao W, Shen Z . Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol. 2012; 18(19):2408-14. PMC: 3353377. DOI: 10.3748/wjg.v18.i19.2408. View

11.

Ramos C, Dotti G . Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011; 11(7):855-73. PMC: 3107373. DOI: 10.1517/14712598.2011.573476. View

12.

Fehniger T, Wylie T, Germino E, Leong J, Magrini V, Koul S . Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res. 2010; 20(11):1590-604. PMC: 2963822. DOI: 10.1101/gr.107995.110. View

13.

Jakubovic B, Jothy S . Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol. 2007; 82(2):184-9. DOI: 10.1016/j.yexmp.2006.10.010. View

14.

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

15.

Li B, Liu H, Shang H, Li P, Li N, Ding H . Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci. 2013; 13(3):703-9. PMC: 3824453. DOI: 10.4314/ahs.v13i3.26. View

16.

Subklewe M, von Bergwelt-Baildon M, Humpe A . Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. Transfus Med Hemother. 2019; 46(1):15-24. PMC: 6558337. DOI: 10.1159/000496870. View

17.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

18.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai S . Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016; 126(8):3036-52. PMC: 4966331. DOI: 10.1172/JCI83416. View

19.

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T . Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology. 2019; 97(5):277-285. DOI: 10.1159/000501281. View

20.

Song M, Park B, Uhm J . Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies. Int J Mol Sci. 2019; 20(20). PMC: 6834308. DOI: 10.3390/ijms20205010. View